Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

9.630 +0.270 (+2.88%)
Streaming Delayed Price Updated: 3:34 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neuropace, Inc. - Common Stock

< Previous 1 2 3 4 Next >
NeuroPace Revenue Jumps 22 Percent in Q2
Via The Motley Fool
NeuroPace (NPCE) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
NeuroPace Reports Record Q2 Revenue
Via The Motley Fool
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Analyst Expectations For NeuroPace's Future
 
Via Benzinga
What 4 Analyst Ratings Have To Say About NeuroPace
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
The Latest Analyst Ratings For NeuroPace
 
Via Benzinga
Earnings Scheduled For August 12, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?
NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA pathway discussions. 
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April
 
Via Benzinga
Topics Stocks
There are notable gap-ups and gap-downs in today's session.
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings
 
Via Benzinga
Tower Semiconductor Posts Upbeat Earnings, Joins Nutex Health, Kornit Digital, Tencent Music Entertainment And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Kura Sushi Posts Downbeat Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Earnings Scheduled For March 4, 2025
 
Via Benzinga
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday. 
Via Benzinga
Topics Stocks
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q2 2024
NPCE stock results show that NeuroPace beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
NPCE Stock Earnings: NeuroPace Meets EPS, Beats Revenue for Q1 2024
NPCE stock results show that NeuroPace met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q4 2023
NPCE stock results show that NeuroPace beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.